Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 181

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part II, Item 3
Chunk 181
---
8, Mr. Moss was also a member of the Board. Mr. Moss was audit committee chair for Qilian International
Holding Groups LTD. from December 2020 to February 2022 and served as a director and audit committee chair of Xiangtai Food Co from Aug
2019 to Aug 2020 and was a director of Pegasi Energy Resources Corporation from May 2007 to January 2014 and was a founding investor in
Reliant Service Group LLC which sold in 2015 to a leading private equity firm. From 1996 until 2001 he served as Managing Partner at a
Seattle based venture capital firm, The Phoenix Partners. From November 2010 until October 2011, Mr. Moss was the Chief Executive Officer,
sole director and a majority shareholder of Tamandare Explorations Inc. a private specialty pharmaceutical company. In October 2011 Tamandare
Explorations engaged in a merger transaction pursuant with Tonix Pharmaceuticals Holding Corp., which at the time had its common stock
listed on the OTC Bulletin Board and is currently listed on Nasdaq Capital Market. In connection with the merger transaction Mr. Moss
resigned as Tamandare Explorations Chief Executive Officer and a member of its board of directors. From 2001 until the formation of INmune
Bio in 2015, Mr. Moss has invested in healthcare technology companies. Mr. Moss holds an MBA from Rice University and a BA in Economics
from the University of California, San Diego.

37

For serving as the Company’s
President and Chief Executive Officer, Mr. Moss’s compensation paid by the Company will continue at its current amount pursuant
to his previous disclosed employment agreement, between Mr. Moss and the Company, dated January 1, 2021, with an annual base salary of
$408,722 and remain eligible for an annual discretionary bonus with a target amount of 40% of his then current base salary as determined
by the Board and/or compensation committee of the Board in its discretion based upon the achievement of corporate and/or individual objectives
that are determined in the sole discretion of the Board. Mr. Moss will not receive any additional compensation for serving as a member
of the Board. The terms of employment of Mr. Moss as the Company’s President and Chief Executive Officer will be revisited by the
Compensation Committee and the Board and disclosed to the market in the future.

There are no arrangements
or understandings between Mr. Moss and any other